Combined Modality Management of Sinonasal Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma in a Young Adult-Report of a Rare Case.


Journal

Journal of adolescent and young adult oncology
ISSN: 2156-535X
Titre abrégé: J Adolesc Young Adult Oncol
Pays: United States
ID NLM: 101543508

Informations de publication

Date de publication:
08 2019
Historique:
pubmed: 18 4 2019
medline: 22 7 2020
entrez: 18 4 2019
Statut: ppublish

Résumé

Sinonasal anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) without nodal involvement is extremely rare and the rarity of this tumor often leads to diagnostic dilemma. It has been predominantly reported in pediatric, adolescent and young adult patients, mostly of Asian origin. A 21-year-old female patient presented with history of epistaxis for 1 year. On clinical and radiological examination, there was a 5 cm mass in the right nasal cavity, ethmoid, and frontal sinus. Biopsy at a local center had shown moderately differentiated squamous cell carcinoma. Rebiopsy at our center showed possibility of a hematolymphoid malignancy(pancytokeratin-, CD45+, CD3-, CD20-) and further immunohistochemistry studies(CD4+, CD43+, CD30+, ALK+) revealed ALK-positive ALCL. Rest of the lymphoma work-up was essentially normal and she had stage IE disease. She was treated with a combination of four cycles of cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisolone (CHOP) regimen followed by local radiotherapy (36 Gray/20 fractions/4 weeks) by three-dimensional conformal technique. She tolerated the treatment well without any severe toxicity and had complete clinical and radiological response. At last follow-up visit, 40 months from the initial diagnosis, she was alive and disease free. Sinonasal ALK-positive ALCL is a rare tumor, which can be effectively treated with a combination of multiagent CHOP/CHOP-like regimen and local conformal radiotherapy.

Identifiants

pubmed: 30994389
doi: 10.1089/jayao.2018.0158
doi:

Substances chimiques

Vincristine 5J49Q6B70F
Cyclophosphamide 8N3DW7272P
Prednisolone 9PHQ9Y1OLM
ALK protein, human EC 2.7.10.1
Anaplastic Lymphoma Kinase EC 2.7.10.1
Daunorubicin ZS7284E0ZP

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

469-476

Auteurs

Ahitagni Biswas (A)

1Department of Radiotherapy and Oncology, All India Institute of Medical Sciences, New Delhi, India.

Bharti Devnani (B)

1Department of Radiotherapy and Oncology, All India Institute of Medical Sciences, New Delhi, India.

Shipra Agarwal (S)

2Department of Pathology, All India Institute of Medical Sciences, New Delhi, India.

Mehar Chand Sharma (MC)

2Department of Pathology, All India Institute of Medical Sciences, New Delhi, India.

Atul Sharma (A)

3Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH